Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

The launch of UpSpring Stomach Settle Drops is causing an uproar as this revolutionary product is reversing the GLP1 side ...

The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and make those costs more transparent.

Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for ...

Jim Cramer, host of Mad Money, recently discussed some of the significant challenges the alcohol industry is facing. He pointed out that as the end of January approaches, the wine and spirits industry ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.